The legal version of this report can be viewed at https://baseballnewssource.com/markets/barclays-plc-initiates-coverage-on-astrazeneca-plc-azn/492969.html.
According to an update released by analysts at Liberum Capital the broker has now set a "Buy" rating on shares of AstraZeneca PLC (LON:AZN) with a price target of 5100. Berenberg Bank reissued a buy rating on shares of AstraZeneca plc in a report on Tuesday, February 21st. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 6,000 ($72.39) price target on shares of AstraZeneca plc in a report on Wednesday, November 30th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company. Jefferies International have set a target price of 5350 GBX on its stock.
Shares of AstraZeneca plc (NYSE:AZN) opened at 29.41 on Tuesday. The short ratio in the company's stock is documented at 3.85 and the short float is around of 1.08%.
AstraZeneca PLC (AZN) stock price ended its day with loss -0.31% and finalized at the price of $29.41. AstraZeneca plc has a 12 month low of $25.55 and a 12 month high of $35.04. The stock of AstraZeneca plc (LON:AZN) earned "Outperform" rating by BNP Paribas on Thursday, July 23. The difference between the expected and actual EPS was $0.02/share, which represents an Earnings surprise of 3.4%. The company had revenue of $5.59 billion for the quarter, compared to the consensus estimate of $5.43 billion. AstraZeneca PLC P/E (price to earnings) ratio is 21.43 and Forward P/E ratio of 15.06. The firm's revenue was down 12.7% compared to the same quarter a year ago. The stock next year first quarter current estimate trend for EPS was for $0.42 and on annual basis FY 2016 estimate trends at current was for $1.85 as compared to one month ago of $2.15, and for next year per share earnings estimates have $2.00.
"AstraZeneca plc (AZN) Receives New Coverage from Analysts at Barclays PLC" was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of global copyright and trademark legislation.
The firm also recently disclosed a semiannual dividend, which will be paid on Monday, March 20th. Stockholders of record on Thursday, May 18th will be paid a GBX 43 ($0.53) dividend. It has a dividend yield of 6.46%.
On 2/10/2014 AstraZeneca plc announced a special dividend of $1.90 2.79% with an ex dividend date of 2/19/2014 which will be payable on 3/24/2014.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Pacad Investment Ltd. acquired a new position in shares of AstraZeneca plc during the fourth quarter worth $115,000. Acrospire Investment Management LLC now owns 3,606 shares of the company's stock worth $118,000 after buying an additional 3,300 shares during the period. Finally, Premier Asset Managment LLC boosted its stake in shares of AstraZeneca plc by 83.9% in the third quarter. Fisher Asset Management LLC now owns 1,977,585 shares of the company's stock worth $64,983,000 after buying an additional 1,638,606 shares during the last quarter.
Analysts' mean recommendation for AstraZeneca PLC (AZN) stands at 2.20.